Welcome Guest! Create an Account login email: password: remember me: BASKETBALL Latest News News Archive Schedule/Results Multi-Media Recruiting FOOTBALL Latest News News Archive Schedule/Results Multi-Media Recruiting MESSAGE BOARD Message Home - Ohio Basketball - Ohio Basketball Recruiting - The O Zone - Ohio Football - Ohio Football Recruiting - Ohio Volleyball - Ohio Baseball - Ohio Olympic Sports... - General OU Discussion... - Website Feedback... - Posting Policy Edit My Profile Private Messages Logout CHAT LINKS site searchcontact usabout usadvertise with ushelp Message Board BobcatAttack.com Message Board General Ohio University Discussion/Alumni Events Topic:  New studies on treatments show improvements Topic:  New studies on treatments show improvements Author Message L.C. General User Member Since: 8/31/2005 Location: United States Post Count: 10,595 Status: Offline     New studies on treatments show improvements    Posted: 6/25/2020 11:50:05 PM  First, a study where they gave HCQ early, in reasonable dose, as soon as people tested positive, and they also monitored zinc levels: https://www.sciencedirect.com/science/article/pii/S147789... Average days hospitalized was reduced from 9.2 days to 7.3 days. Patient ending up in the ICU was reduced from 6.8% to .8%, and the death rate was reduced from 3.1% to 0.5%. In total, "poor clinical outcomes", as defined by death, transfer to ICU, or hospitalization for over 10 days, was reduced from 17.6% to 3.9%. In 0.67% of patients, QTc elongation was noted, and they were removed from HCQ. No deaths were reported due to HCQ. For severe cases, Tocilizumab, which targets IL-6 receptors to block cytokine storms, works: https://www.thelancet.com/journals/lanrhe/article/PIIS266... Looking at severe cases, 20% died with standard care, compared to 7% who got Tocilizumab. So does Anakinra, which blocks IL-1 receptors: https://www.thelancet.com/journals/lanrhe/article/PIIS266... Patients included people with severe bilateral pneumonia. Negative outcomes (admission to ICU or death) occurred in 25% of cases that received Anakinra, compare to 75% of patients on standard care. Anakinra reduced both mortality and the need for mechanical ventilation without significant side effects. �We have two ears and one mouth so that we can listen twice as much as we speak.� ― Epictetus Back to Top Showing Replies:   1 - 1  of 1 Posts Jump to Page:   1 View Other 'General Ohio University Discussion/Alumni Events' Topics                                                                                                                                                                                                                                                                               WHO'S ONLINE There are 39 Active Visitors on BobcatAttack.com 39 Guests 0 Registered Users There are no other users looking at this page.

Copyright ©2026 BobcatAttack.com. All rights reserved.  |  Privacy Policy  |  Terms of Use
Partner of USA TODAY Sports Digital Properties